Urothelial cell carcinoma in situ (CIS) of the bladder is a superficially diffusive and highly discohesive disease. The authors analyzed the expression of some adhesion molecules (e-cadherin and Ep-CAM) and MUC1 in 32 unifocal and multifocal bladder urothelial cell CIS in an attempt to clarify this discohesion. E-cadherin was strongly expressed, in more than 75% of the cases. The presence of methylation of the CDH1 e-cadherin promoter gene was also investigated, but methylation was found in only one case. Ep-CAM was present in all the cases with a heterogeneous staining pattern. Similarly, MUC1/episialin was variously present in 94% of the cases without a polarized staining pattern and was expressed more strongly in cases with multifocal disease. Because loss of MUC1 polarization leads to interference with cell—cell adhesion mechanisms mediated by cadherins, these findings help explain why bladder urothelial cell CIS often shows a discohesive morphology and multifocality despite a strongly expressed adhesion molecule profile. Finally, Ep-CAM expression might provide some support for future target therapy trials.
Murphy WM, Grignon DJ, Perlman EJ, eds. Carcinoma in situ. In: Tumors of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumor Pathology. Series 4. Fascicle 1. Washington, DC: Armed Forces Institute of Pathology; 2004:276-280.
2.
Witjes JABladder carcinoma in situ in 2003: state of the art. Eur Urol.2004;45:142-146.
3.
Shen SS, Lerner SP, Muezzinoglu B., Truong LD, Amiel G., Wheeler TMProstatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol . 2006;37:726-734.
4.
McKenney JK, Gomez JA, Desai S., Lee MW, Amin MBMorphological expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion . Am J Surg Pathol. 2001;25:356-362.
5.
Sun W., Herrera GAE-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma and invasive transitional cell carcinoma . Hum Pathol. 2002;33:996-1000.
6.
Shariat SF, Pahlavan S., Baseman AG, et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 ;57:60-65.
7.
Byrne RR, Shariat SF, Brown R., et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term follow-up. J Urol. 2001;165:1473-1479.
8.
Sun W., Herrera GAE-cadherin expression in invasive urothelial carcinoma. Ann Diagn Pathol. 2004;8:17-22.
9.
Bindels EMJ , Vermey M., van den Beemd R., Dinjens WNM , Van Der Kwast THE-cadherin promotes intraepithelial expansion in an in vitro model of carcinoma in situ. Cancer Res. 2000;60:177-183.
10.
Rieger-Christ KM, Cain JW, Braasch JW, et al. Expression of classic cadherin type 1 in urothelial neoplastic progression. Hum Pathol. 2001;32:18-23.
11.
Clairotte A. , Lascombe I., Fauconnet S., et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gammacatenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol. 2006;125:119-126.
12.
Bringuier PP , Giroldi LA, Umbas R., Shimazui T., Schalken J.Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors. Int J Cancer. 1999;83:591-595.
13.
Esteller M. , Corn PG, Baylin SB, Herman JGA gene hypermethylation profile of human cancer . Cancer Res. 2001 ;61:3225-3229.
14.
Wesseling J. , van der Valk SW, Vos HL, Sonnenberg A., Hilkens J.Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol . 1995;129:255-265.
15.
Wesseling J. , van der Valk SW, Hilkens J.A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell. 1996;7:565-577.
16.
Kohlgraf KG , Gawron AJ, Higashi M., et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 2003;63:5011-5020.
17.
Rakha EA, Boyce RW, Abd El-Rehim D., et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005;18:1295-1304.
18.
de Roos MA, van der Vegt B., Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumor characteristics and clinical outcome in "pure" ductal carcinoma in situ of the breast. Histopathology. 2007;51: 227-238.
19.
van der Vegt B., de Roos MA, Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumor characteristics and clinical outcome in invasive ductal carcinoma of the breast. Histopathology . 2007 ;51:322-335.
20.
Winter MJ, Nagtegaal ID, van Kneken JH, Litvinov SVThe epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003;163:2139-2148.
21.
Lopez-Beltran A., Sauter G., Gasser T., et al. Infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. WHO Classification of Tumours. Lyon, France: IARC Press;2004:119-120.
22.
Pu RT, Laitala LE, Clark DPMethylation profiling of urothelial carcinoma in bladder biopsy and urine . Acta Cytol. 2006;50:499-506.
23.
Dhawan D., Hamdy FC, Rehman I., et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol. 2006;209:336-343.
24.
Horikawa Y. , Sugano K., Shigyo M., et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high-grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol. 2003 ;169: 1541-1545.
25.
Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res . 2002;8:464-470.
26.
Cardillo RM , Castagna J., Memeo L., DeBernardis E., di Silverio F.Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res. 2000;19:225-33.
27.
Simms MS, Hughes OD, Limb M., Price RM, Bishop MCMUC1 mucin as a tumour marker in bladder cancer. BJU Int. 1999;84:350-352.
28.
Nassar H., Pansare V., Zhang H., et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol. 2004;16:1-6.
29.
Duggan BJ, Gray SB, McKnight JJ, Watson CJ, Johnston SR, Williamson KEOligoclonality in bladder cancer: the implication for molecular therapies . J Urol. 2004; 171:419-425.
30.
Hilkens J., Ligtenberg MJ, Vos HL, Litvinov SVCell membrane-associated mucins and their adhesion-modulating property . Trends Biochem Sci. 1992;17:359-363.
31.
Hoglund M.Bladder cancer, a two phase disease? Semin Cancer Biol. 2007;17:225-232.
32.
Fields AF, Keller AM, Schwartzberg L., et al. Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study. Paper presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, FL. Abstract 508.
